Oral treatment could slow progress of Alzheimer’s disease
Researchers have reported a potential oral treatment for Alzheimer’s disease (AD) that slowed its progression over a period of at least 18 months. Developed by Singaporean company TauRx Pharmaceutics, the scientists based in Aberdeen, UK, report that hydromethylthionine mesylate (HMTM) could be the first oral treatment for… Read More